-
公开(公告)号:US20110034437A1
公开(公告)日:2011-02-10
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/55 , C07D261/20 , A61K31/42 , A61K31/438 , C07D498/10 , A61P25/00 , A61P3/00 , A61P9/00 , A61P1/08 , A61P25/28 , A61P25/30 , A61P25/20 , A61P3/04
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US09149465B2
公开(公告)日:2015-10-06
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: C07D261/04 , A61K31/5377 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US08765735B2
公开(公告)日:2014-07-01
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A01N43/00 , A61K31/55 , A01N43/42 , A61K31/44 , A01N43/80 , A61K31/42 , C07D261/02 , C07D401/00
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US20110028478A1
公开(公告)日:2011-02-03
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/5377 , C07D261/04 , A61K31/42 , A61P29/00 , A61P27/06 , A61P9/10 , A61P37/00 , A61P17/00 , A61P25/28 , A61P1/08 , A61P25/30 , A61P9/12 , A61P3/04 , C07D413/12 , A61K31/4439 , A61K31/506 , A61K31/501 , C07D413/10 , A61K31/4245 , A61K31/4709
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
5.
公开(公告)号:US20110028482A1
公开(公告)日:2011-02-03
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/42 , C07D417/14 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/427 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D417/10 , A61K31/428 , C07D403/10 , C07D401/10 , A61K31/4709 , A61P1/00 , A61P3/00 , A61P9/00 , A61P17/00 , A61P25/00 , A61P27/06 , A61P29/00
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US08927551B2
公开(公告)日:2015-01-06
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/424 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D403/10 , C07D401/10 , C07D417/04 , C07D417/14 , C07D413/14 , C07D261/04
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US08957049B2
公开(公告)日:2015-02-17
申请号:US12901421
申请日:2010-10-08
申请人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
摘要翻译: 本发明提供了由式(I),(II),(III),(IV),(V)或(VI)或其子类中的任何一种包含的化合物及其药学上可接受的组合物。 本发明还提供了通过施用治疗有效量的化合物或组合物来治疗FAAH介导的疾病,病症或病症的方法,所述化合物或组合物包含式(I),(II),(III),(IV), (Ⅴ)或(Ⅵ)或其子代的药物给予有需要的患者。 另外,本发明提供了通过施用治疗有效量的包含式(I),(II),(III),(IV),(V)或((IV))的化合物的化合物或组合物来抑制FAAH的方法, VI)或其子集合。
-
公开(公告)号:US08329675B2
公开(公告)日:2012-12-11
申请号:US13049779
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号:US20110224171A1
公开(公告)日:2011-09-15
申请号:US13049779
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/69 , A61P29/00 , A61P37/00 , A61P25/24 , A61P25/02 , A61P25/00 , A61P27/06 , A61P9/00 , A61P25/06
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号:US20090099131A1
公开(公告)日:2009-04-16
申请号:US11870130
申请日:2007-10-10
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
-
-
-
-
-
-
-
-